A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

Original title: “PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval”

Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.

Original title: “Lilly builds commercial case for GLP-1 products over Novo with indirect analyses”

Time has run out on BioNTech's bid to locate buyers for sites in Idar-Oberstein, Marburg and Tübingen. Including staff at a Singapore plant also slated for closure, the move could impact 1,860 jobs.

Original title: “BioNTech to close German manufacturing plants after failing to find buyers”

Strange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into a new role.

Original title: “No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins”

Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.

Original title: “Trend of women-led M&A fades in 2026 with just two deals so far”

It’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.

Original title: “Biopharma needs to reward scientists' judgment”

It’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.

Original title: “Biopharma needs to reward scientists' judgment”

HRSA administers this grant using funding made available by the Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE) from the Patient Centered Outcomes Research Trust Fund (PCORTF) and awarded for this purpose to JHU. ASPE/PCORTF supports this multi-agency data linkage project to build further data capacity. Supplemental funding was previously awarded in fiscal year (FY) 2024 and FY25 to initiate the data linkage and user testing process. This award is a continuation

Original title: “Autism Longitudinal Data Project and Linking the Boston Birth Cohort and Pregnancy to Early Life Longitudinal Data System and Community-Level Health Databases: A Longitudinal Cohort of Mother-Child Dyads”

HRSA is announcing a supplemental award to Morgan State University (MSU), a current HRSA awardee for the Maternal Health Research Collaborative for Minority Serving Institutions (MH-RC-MSI) Coordinating Center (CC). HRSA administers this grant using funding made available by the Department of Health and Human Services' Assistant Secretary for Planning and Evaluation's Patient-Centered Outcomes Research Trust Fund. The Assistant Secretary for Planning and Evaluation's Patient-Centered Outcomes Re

Original title: “Notice of Supplemental Award; Maternal Health Research Collaborative for Minority-Serving Institutions Coordinating”

In this webinar, experts from SK pharmteco’s European and North American sites share practical experience addressing these challenges across the linker-payload development lifecycle—from facility and containment strategy through process and analytical development, scale-up, cleaning, and final product release. Case-based examples will illustrate how integrated chemistry, engineering, analytical, and industrial hygiene strategies can reduce technical risk and support the rapid transition of emerg

Original title: “Webinar: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis”

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.

Original title: “Beam sues 2 biotechs, alleging theft of base editing trade secrets”

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

Original title: “Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill”